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INTRODUCTION 
The mainstays of therapy for heart failure 
with reduced ejection fraction (HFrEF) have 
traditionally been angiotensin converting 
enzyme inhibitors (ACEI) or angiotensin 
receptor blockers (ARB), beta-blockers, 
aldosterone receptor antagonists, and 
diuretics for symptomatic relief (1). With few 
advances made over the past few decades, the 
principles of treating HFrEF have been 
revolutionized following the results of the 
PARADIGM-HF trial (Prospective 
comparison of ARNI with ACEI to 
Determine Impact on Global Mortality and 
morbidity in Heart Failure) in 2014. The trial 
compared the novel agent sacubitril/valsartan 
(Entresto®) to Enalapril (1). 
Sacubitril/valsartan is a combination 
angiotensin II receptor blocker-neprilysin 
inhibitor (ARNI) that replaces traditional 
ACEI and ARB therapy in the treatment of 
HFrEF. The PARADIGM-HF trial was 
stopped early due to overwhelming evidence 
of decreased mortality and decreased HFrEF 
related hospitalizations with 
sacubitril/valsartan when compared to 
Enalapril (2). Since the study was released, 
the American College of Cardiology (ACC), 
the American Heart Association (AHA), and 
the Heart Failure Society of America (HFSA) 
released updated guidelines in May 2016. 
Sacubitril/valsartan now holds a Class I 
Recommendation for the treatment of HFrEF 
in patients with New York Heart Association 
(NYHA) class II or III heart failure (3). These 
recommendations were further upheld in the 
recently released 2017 ACC/AHA/HFSA 
Focused Update for the Management of 
Heart Failure (4).  
 
ACC/AHA/HFSA 2017 Guidelines: 
Class I 
Recommendation to 
reduce mortality and 
morbidity in patients 
with chronic HFrEF 
Inhibition of RAAS 
system with ACEI, ARB, 
or ARNI in conjunction 
with beta-blockers, 
aldosterone antagonists. 
Class I 
Recommendation for 
patients with HFrEF 
NYHA II or III who 
previously tolerated 
an ACEI or ARB. 
Recommended to replace 
ACEI or ARB with ARNI 
therapy to further reduce 
morbidity and mortality. 
 
Since the release of this trial, 
sacubitril/valsartan use has been growing 
rapidly among heart failure patients, and 
hospitalists will encounter this medication on 
a more regular basis. Thus, it is imperative for 
hospitalists to understand the clinical data 
and side effect profile to manage patients on 
sacubitril/valsartan in the hospital setting. 
 
Role of Neprilysin 
Neprilysin is a multiple substrate, membrane-
bound neutral endopeptidase enzyme present 
in many tissues throughout the body with the 
highest concentrations in the renal tissue (1, 
5). Neprilysin is often referred to as a 
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“promiscuous” enzyme for its ability to 
degrade multiple neurohormonal substrates, 
including atrial natriuretic peptide (ANP), 
brain natriuretic peptide (BNP), C-type 
natriuretic peptide (CNP), angiotensin II, 
bradykinin, adrenomedullin, glucagon, 
vasoactive intestinal peptide (VIP), and 
substance P (1). Through the inhibition of 
neprilysin, vasodilatory substances 
(specifically: ANP, BNP, and CNP) remain 
in an active form and promote vasodilation, 
diuresis, and prevent negative tissue 
remodeling of the heart (5, 6). 
 
Evidence of Efficacy 
The PARADIGM-HF trial was a 
groundbreaking study demonstrating the 
superiority of ARNI therapy over Enalapril in 
the treatment of HFrEF. Investigators for the 
trial included patients with NYHA class II, 
III, and IV heart failure who had an ejection 
fraction of less than 40%. These patients 
were also already receiving the standard of 
care medical therapy including ACEI, ARB, 
beta-blockers, and aldosterone antagonists 
(7). Primary end-points included death from 
cardiovascular causes and first 
hospitalizations for heart failure. The trial 
ended early, after only 27 months, because 
the primary outcomes were met before the 
scheduled conclusion of the study. 
Difference in death from cardiovascular 
causes or first hospitalizations for worsening 
heart failure was significant between the two 
groups with 21.8% in the sacubitril/valsartan 
group and 26.5% in the Enalapril group (1). 
Furthermore, 27 months after study initiation, 
sacubitril/valsartan showed a 20% relative 
risk reduction in hospitalizations and heart-
failure mortality compared to Enalapril (6). 
 
Clinical Use of Sacubitril/valsartan              
How can hospitalists use this information to 
initiate and manage sacubitril/valsartan use 
in patients with heart failure?  
Current guidelines, put forth by the 
ACC, AHA, and HFSA, recommend that 
patients with HFrEF NYHA II or III, who 
have previously tolerated an ACEI or an 
ARB, be switched to sacubitril/valsartan to 
further reduce morbidity and mortality (3). 
This switch from ACEI/ARB therapy to 
ARNI therapy usually occurs in the 
outpatient setting, but may be carefully 
considered in clinically stable inpatients with 
normal vital signs and volume status. A 
starting dose of 49 mg sacubitril/ 51 mg 
valsartan twice daily is recommended after a 
36 hour ACEI washout period (2). At a 
follow-up appointment in two to four weeks 
from initiation, the dose can be increased to 
the target dose of 97 mg of sacubitril/ 103 mg 
valsartan twice daily barring any side effects 
(8). If patients were not on optimal 
ACEI/ARB therapy prior to starting ARNI 
therapy, or were on a low ACEI/ARB dose, 
then it is recommended to start at 24 mg 
sacubitril/ 26 mg valsartan twice daily (2). 
This lower initial dose is also recommended 
in patients with severe renal impairment and 
moderate hepatic impairment (2).  
 
FDA Approved Indications: 
Indications: Approved 
for HFrEF NYHA II-IV 
To be used with other 
currently approved 
heart failure therapies. 
 
FDA Dosing Guidelines: 
 
 
Recommended Starting 
Dose: 
49 mg sacubitril/ 51 
mg valsartan. Titrate 
up every 2-4 weeks to 
reach target dose of 97 
mg sacubitril/ 103 mg 
valsartan. 
Dosing Adjustments for 
Patients Not Currently 
taking ACEI or ARB 
therapy, Severe Renal 
Impairment (GFR 
<30mL/min/1.73 m2), or 
Hepatic Impairment 
(Child-Pugh B 
classification): 
 
Starting dose is 24 mg 
sacubitril/ 26 mg 
valsartan. Titrate the 
Dose up every 2-4 
weeks to target dose 
of 97 mg sacubitril/ 
103 mg valsartan. 
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Upon initiation of sacubitril/valsartan 
there are few statistically significant side 
effects that clinicians should be aware of. 
Sacubitril/valsartan has superior vasodilator 
effects compared to Enalapril and thus has 
higher rates of symptomatic hypotension (1). 
However, there was no increase in the rate of 
discontinuation of ARNI in PARADIGM-HF 
due to this symptomatic hypotension (6). 
Furthermore, the concomitant use of diuretics 
in the treatment of heart failure may 
exacerbate this hypotension. Many clinicians 
decide to decrease diuretic doses when 
initiating sacubitril/valsartan to combat this 
potential hypotension and then titrate the 
diuretic up or down depending on the 
patient’s clinical response. 
Hyperkalemia is also a serious 
concern when using sacubitril/valsartan, thus 
patients receiving this drug should have their 
potassium levels closely monitored. 
Furthermore, patients at a higher risk for 
hyperkalemia (such as patients with renal 
failure, diabetes, or hypoaldosteronism) 
should not concomitantly be prescribed 
potassium-sparing diuretics, potassium 
supplements, or any medication that may 
significantly increase potassium (2).  
The most serious side effect of 
sacubitril/valsartan treatment is the 
development of angioedema which occurred 
at a similar rate with Enalapril in 
PARADIGM-HF (6). Sacubitril/valsartan 
use should be avoided in patients with a 
history of angioedema (3). Moreover, for 
patients on ACEI therapy that are switching 
to ARNI therapy it is recommended to have a 
36-hour washout period to prevent this life-
threatening angioedema (3, 8). 
A common occurrence among 
hospitalists now is to admit patients who are 
already established on sacubitril/valsartan. 
There is limited data on how physicians 
should handle this medication in terms of 
continuing or withholding its use while 
inpatient. Most clinicians continue 
sacubitril/valsartan if the patient is clinically 
stable and normotensive. On the other hand, 
if the patient presents in an acute renal 
failure, decompensated heart failure, or is 
hypotensive, sacubitril/valsartan is usually 
withheld until the patient stabilizes. Since 
there is limited data, clinicians should use 
their clinical judgment on whether to 
continue or withhold sacubitril/valsartan in 
newly admitted patients depending on the 
patient’s presentation and the physician’s 
experience and comfort level.   
Patients admitted to the hospital for 
heart failure exacerbations provide 
physicians with a unique opportunity to 
intervene and start those patients on 
sacubitril/valsartan. Unfortunately, there is 
limited data on starting patients on 
sacubitril/valsartan in the hospital setting. 
Nevertheless, hospitalists can be an 
important resource in identifying patients 
who could benefit from this medication. If 
sacubitril/valsartan is to be started inpatient, 
it is recommended to wait until the patient 
stabilizes from their acute heart failure 
exacerbation. For instance, it is wise to wait 
until the patient is normotensive, has normal 
volume status, and laboratory measurements 
have returned to baseline. Furthermore, if 
sacubitril/valsartan is initiated in the hospital, 
it is necessary to ensure close follow-up with 
the patient’s primary care provider or 
cardiologist to monitor symptoms, 
electrolytes and titrate the medication. 
The main concern among clinicians 
and patients alike is the cost associated with 
sacubitril/valsartan. The cost of 
sacubitril/valsartan has been estimated 
around $12.50 per day which adds up to 
$4560 per year (9). This figure is many times 
the cost of an ACEI or ARB therapy which 
averages to less than ten cents per day (9). On 
the other hand, heart failure admission rates 
are expected to decline with 
sacubitril/valsartan use. A recent study, 
which performed a cost-effective analysis 
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comparing sacubitril/valsartan and Enalapril, 
estimated there would be 220 fewer hospital 
admissions per 1000 patients over 30 years 
when using sacubitril/valsartan (10). Thus, 
medical savings from reduced hospital 
admissions could be significant. An 
individual patient’s coverage and prior 
authorization requirements can be quickly 
assessed using an online calculator 
(https://www.sacubitril/valsartan-
coverage.com). 
 
ARNI Therapy: Current 
Recommendations and Future Research 
Given all the data, sacubitril/valsartan 
represents a revolution in the treatment of 
HFrEF. The 2017 ACC/AHA/HFSA 
Focused Update of the Guidelines for 
Management of Heart Failure gives 
sacubitril/valsartan a Class I 
recommendation (4). This endorsement has 
solidified the use of sacubitril/valsartan for 
the management of HFrEF. Consequently, 
hospitalists will be seeing this medication 
more and more in the inpatient setting. In 
addition, hospitalization may represent an 
ideal opportunity to initiate stable patients on 
sacubitril/valsartan, which provides a 20% 
relative risk reduction in cardiovascular death 
and a significant decrease in heart failure 
hospitalizations as compared to Enalapril. 
Future studies are currently underway to 
compare the effects of ARNI with other 
standard treatments, evaluate the use of 
ARNI therapy in patients with Heart Failure 
with Preserved Ejection Fraction (HFpEF), 
and evaluate the use of ARNI therapy after an 
acute myocardial infarction. Of particular 
interest, the upcoming TRANSITION trial 
will compare in-hospital initiation of 
sacubitril/valsartan to initiation after hospital 
discharge in HFrEF patients recently 
hospitalized for an acute decompensation. 
The study is expected to be completed in 
2018. 
The PARADIGM-HF trial paved the 
way for these trials and set the management 
of HFrEF patients on a new path to decreased 
patient mortality, decreased hospitalizations, 
and improved quality of life while living with 
this devastating disease. 
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